Editas Medicine reported its financial results for the first quarter of 2025 on May 12, 2025. The Company's cash, cash equivalents, and marketable securities were $221.0 million as of March 31, 2025, compared to $269.9 million as of December 31, 2024.
Collaboration and other research and development revenues increased to $4.7 million for the three months ended March 31, 2025, up from $1.1 million for the same period in 2024, primarily due to the recognition of remaining deferred revenue from a closed collaboration agreement. Operating expenses totaled $80.8 million in Q1 2025, a significant increase from $68.1 million in Q1 2024, driven by $40.9 million in restructuring and impairment charges.
The net loss for the first quarter of 2025 was $76.1 million, an increase from the $62.0 million net loss in Q1 2024. The Company expects its existing cash, cash equivalents, and marketable securities, along with retained portions of Vertex Pharmaceuticals payments, to fund operating expenses and capital expenditure requirements into the second quarter of 2027.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.